In English | En español
Questions About Cancer? 1-800-4-CANCER

Clinical Trials (PDQ®)

  • First Published: 3/17/2009
  • Last Modified: 3/1/2011

Page Options

  • Print This Page
  • Email This Document
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
LiveHelp online chat
Phase II Study of a Computerized Smoking Cessation Clinical Decision Support System in Assisting Physicians Counsel Patients Who Smoke Cigarettes

Alternate Title
Basic Trial Information
Objectives
Entry Criteria
Expected Enrollment
Outcomes
Outline
Trial Contact Information
Registry Information

Alternate Title

Computer-Assisted Stop-Smoking Program in Helping Doctors Counsel Patients Who Smoke Cigarettes

Basic Trial Information

PhaseTypeStatusAgeSponsorProtocol IDs
Phase IIBehavioral study, Educational/Counseling/Training, Health services researchActive18 and overNCIVCC-08186
08-186, IRB#00000486, NCT00865553

Objectives

  1. Test the hypothesis that the clinical decision support system will improve the rate at which physicians assist their patients with smoking cessation by providing information and recommendations on smoking cessation resources.
  2. Assess whether exposure to information and recommendations facilitated by the smoking cessation-personal digital assistant (SC-PDA) will increase the rate at which patients make at least 1 attempt to quit smoking in the month following the physician visit.
  3. Assess whether exposure to information and recommendations facilitated by the SC-PDA will increase the reported use of counseling and pharmacotherapy during those attempts over that observed with a smoking status identification system alone.
  4. Evaluate the acceptance of the SC-PDA into the workflow of ambulatory care clinics.

Entry Criteria

Disease Characteristics:

  • Current smoker, defined as self-reported smoking most days or every day (patient)

  • Seeks care at a participating Fletcher Allen Health Care primary care clinic (patient)

Prior/Concurrent Therapy:

  • Not specified

Patient Characteristics:

  • Not specified

Expected Enrollment

630

Outcomes

Primary Outcome(s)

Physician adherence to the United States Public Health Service’s Tobacco Use and Dependence Treatment guideline (USPHS Guideline) as measured by the patient exit survey
Patient perception of physician as measured by the patient exit survey and telephone interview
Prevalence of smoking and associated variables as measured by the patient exit survey
Patient interaction with the smoking cessation-personal digital assistant (SC-PDA) as measured by the patient exit survey and telephone interview
Patient report of physician SC-PDA use as measured by the patient exit survey and telephone interview
Aggregate data on accessing SC-PDA screens by each physician as measured by the SC-PDA server log
Generation of patient handouts as measured by the SC-PDA server log, clinic staff focus groups, and telephone interview
Physician self-reported use of SC-PDA as measured by physician interview
Physician opinion on perceived value and barriers to use as measured by physician interview
Clinic staff opinion on the effect of SC-PDA on clinic workflow as measured by clinic staff focus groups

Outline

In weeks 1-12, physicians have access to a smoking status identification system (SSID) that reminds the physician the smoking status of the patient they are evaluating. In weeks 6-12, physicians have access to a computerized smoking cessation clinical decision support system using a hand-held personal digital assistant (SC-PDA) that they can use in the exam room with their patients who smoke. The SC-PDA system assists physicians in recommending and prescribing approved pharmacotherapy; facilitates referral of patients to local counseling resources; prints a tailored handout for a patient listing specific recommendations, instructions, and cessation resources; and generates the necessary documentation to support billing for this intervention.

Patients who visit their physician in weeks 2-6 or weeks 8-12 complete a survey after their clinic visit and undergo a telephone interview 1 month later. Physicians undergo interviews and focus groups are conducted with clinic staff in weeks 12-16.

Trial Contact Information

Trial Lead Organizations

Vermont Cancer Center at University of Vermont

Theodore Marcy, MD, MPH, Principal investigator
Ph: 802-656-3650

Trial Sites

U.S.A.
Vermont
  Burlington
 Vermont Cancer Center at University of Vermont
 Clinical Trials Office - Vermont Cancer Center at University of Vermont
Ph: 802-656-2178

Registry Information
Official Title Clinical Testing of a Decision Support System for Tobacco Use Treatment
Trial Start Date 2009-03-23
Trial Completion Date 2010-08-31 (estimated)
Registered in ClinicalTrials.gov NCT00865553
Date Submitted to PDQ 2009-03-09
Information Last Verified 2011-03-01
NCI Grant/Contract Number CA134817-01, CA22435

Note: The purpose of most clinical trials listed in this database is to test new cancer treatments, or new methods of diagnosing, screening, or preventing cancer. Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test. The therapy or test described in this clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this clinical trial should be consulted before using this protocol.

Back to TopBack to Top